Hyperlipoproteinemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Hardik Patel (talk | contribs) |
Hardik Patel (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
==Medical Therapy== | ==Medical Therapy== | ||
===[[Hyperlipidemia medical therapy in adults | Medical Therapy in Adults]]=== | ===[[Hyperlipidemia medical therapy in adults | Medical Therapy in Adults]]=== | ||
===[[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | | |||
* [[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | |||
* [[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]] | ===Medical Therapy in Children and Adolescents=== | ||
*[[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | Drug therapy of high-risk hyperlipidemia]] | |||
*[[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins for high-risk hyperlipidemia]] | |||
*[[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]] | |||
===[[Hypertriglyceridemia medical therapy | Pharmacotherapy]]=== | ===[[Hypertriglyceridemia medical therapy | Pharmacotherapy]]=== | ||
* [[Statins]] | * [[Statins]] | ||
* [[Niacin]] | * [[Niacin]] | ||
Revision as of 17:14, 26 October 2012
|
Lipoprotein Disorders Microchapters |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]